Baxter International vs Lilly (Eli)
Side-by-side comparison of AI visibility scores, market position, and capabilities
Deerfield IL hospital medical technology (NYSE: BAX) at $10.636B 2024 revenue; Vantive kidney care sold to Carlyle $3.8B (Jan 2025), new CEO Andrew Hider (Sep 2025) competing with ICU Medical for IV solutions and infusion systems.
About
Baxter International Inc. is a Deerfield, Illinois-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BAX) as an S&P 500 component — providing hospitals, nursing homes, ambulatory surgery centers, and home healthcare settings with intravenous (IV) solutions, infusion systems, parenteral nutrition therapies, inhaled anesthetics, advanced surgical equipment, and digital health solutions through approximately 38,000 employees worldwide. In fiscal year 2024, Baxter reported $10.636 billion in revenue from continuing operations with a market capitalization of approximately $15 billion. Baxter has undergone significant strategic transformation: divesting its kidney care business (Vantive) to Carlyle Group for $3.8 billion in January 2025 and its biopharma solutions business for $4.25 billion in 2023, sharpening focus on its three core segments — Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. In July 2025, Baxter appointed Andrew Hider as President and CEO (effective September 2025), bringing operational excellence expertise from his tenure as CEO of ATS (where he doubled revenues and tripled the stock price). Founded in 1931, Baxter introduced the first commercially prepared IV solutions and the first commercially-built kidney dialysis system.
Indianapolis pharma leader (NYSE: LLY) $45.1B FY2024 revenue (+32%); Mounjaro $11.4B + Zepbound $4.9B tirzepatide GLP-1, oral orforglipron Phase 3, $18B manufacturing expansion competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Health Care component — discovering, developing, and commercializing medicines across diabetes, obesity, oncology, immunology, and neuroscience through approximately 43,000 employees worldwide. In fiscal year 2024, Eli Lilly reported revenues of $45.1 billion (+32% year-over-year) — driven by the historic commercial launch of Mounjaro (tirzepatide for type 2 diabetes, $11.4B revenue) and Zepbound (tirzepatide for obesity and obstructive sleep apnea, $4.9B revenue) — making Eli Lilly one of the fastest-growing large pharmaceutical companies in history and elevating its market capitalization above $700 billion at peak 2024 valuation, briefly making Lilly the most valuable healthcare company globally. CEO Dave Ricks' strategic investment in tirzepatide manufacturing capacity — committing $18+ billion to new US manufacturing sites in Indiana, Wisconsin, and North Carolina — reflects Lilly's execution of unprecedented pharmaceutical demand that has consistently outpaced supply since Mounjaro's 2022 approval and Zepbound's 2023 FDA approval for obesity. The GLP-1/GIP dual agonist mechanism (tirzepatide activates both GLP-1 and GIP incretin receptors, versus semaglutide's single GLP-1 activation) produces superior efficacy results — SURMOUNT-1 trial showing 22.5% average body weight loss with tirzepatide versus 15% with semaglutide (Ozempic/Wegovy) — establishing tirzepatide as the most effective approved obesity pharmacotherapy.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.